Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Varicella_vaccine
|
| gptkbp:age |
12 months and older
|
| gptkbp:approves |
gptkb:1995
gptkb:FDA |
| gptkbp:average_temperature |
-15° C to -25° C
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnant women
immunocompromised individuals history of severe allergic reaction to vaccine components |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
1 dose for children 12 months to 12 years
2 doses for individuals 13 years and older |
| gptkbp:financial_performance |
up to 24 months when stored properly
|
| gptkbp:healthcare |
important for public health initiatives
|
| https://www.w3.org/2000/01/rdf-schema#label |
Varivax
|
| gptkbp:is_effective_against |
approximately 90% effective after 1 dose
approximately 98% effective after 2 doses |
| gptkbp:is_standardized_by |
guidelines provided by health organizations
|
| gptkbp:is_used_for |
prevention of varicella (chickenpox)
|
| gptkbp:is_vulnerable_to |
available in many countries
varies by provider live attenuated vaccine generally well tolerated lyophilized powder for reconstitution administered by healthcare professionals decreased hospitalizations due to chickenpox distributed through healthcare providers significantly reduced incidence of chickenpox high efficacy against severe disease adverse events monitored post-vaccination recommended for children and adults without immunity 2 doses recommended CDC recommends vaccination for all children approved for use in the United States educational materials provided to parents introduced in the United States in 1995 monitored for long-term safety ongoing studies on long-term immunity ongoing surveillance for breakthrough cases part of routine childhood immunizations recommended by CDC reduces transmission of varicella updated periodically by health authorities effective in preventing chickenpox in vaccinated individuals |
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:market |
ongoing
|
| gptkbp:side_effect |
fever
injection site reactions mild rash required by FDA |
| gptkbp:traded_on |
Varicella Vaccine Live Attenuated
|